Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
← catalyst calendarNCT05061550 · readout in 1,378 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →. With Parexel.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
630estimated
Sites
97
Countries
Belgium, Canada, France +9
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-04-14 | actual | When the study began enrolling |
| Primary completion | 2030-05-28 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2030-05-28 | estimated | The whole study's end, after follow-up |
| First posted | 2021-09-29 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-23 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Non-small Cell Lung Cancer
Interventions
- Drug: Durvalumab — also filed as MEDI4736, IMFINZI
- Drug: Oleclumab — also filed as MEDI9447
- Drug: Monalizumab — also filed as IPH2201
- Drug: Dato-DXd
- Drug: AZD0171
- Drug: Carboplatin
- Drug: Cisplatin
- Drug: Pemetrexed/Cisplatin
- Drug: Pemetrexed/Carboplatin
- Drug: Carboplatin/Paclitaxel
- Drug: Volrustomig — also filed as MEDI5752
- Drug: Rilvegostomig
Primary outcomes
what the primary-completion date above is the date OFNumber of participants with pathological complete response (pCR)
measured From randomization to approximately 15 weeks after the first dose of study interventions
Number of participants with adverse events (AEs) and serious adverse events (SAEs)
measured Until Day 90 after the last dose of study interventions (Up to approximately 3 years)
Publications
- PMID 40450142 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed